Miraculins Announces Private Placement Offering

February 9, 2010

WINNIPEG, Manitoba – February 9, 2010 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces a non-brokered private placement offering (the “Offering”) of up to 7,150,000 units (“Units”) at a price of $0.07 per Unit for gross proceeds of up to $500,500. Each Unit will be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 12 months from the date the Warrant is issued. The Warrant is callable, at the option of the Company, in the event its Shares trade at or above $0.14 per Share for any 20 out of 30 consecutive trading days.

Certain persons may assist the Company by introducing potential subscribers for the Offering and, subject to compliance with applicable legislation, will be entitled to receive a finder’s fee, payable in cash and share purchase warrants, as permitted by law.

The net proceeds of the Offering will be used for the Company’s research and development program and for working capital purposes.

The Offering is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange.

About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on non-invasive tests for unmet clinical needs. Miraculins is bridging the gap between commercially available diagnostic tests and research conducted at leading research institutions around the world.

For more information, please contact:
Christopher J. Moreau
President and CEO
Miraculins Inc.
Ph: 204-477-7599
Fax: 204-453-1546

Share This Story